New drug cocktail may make inoperable liver cancer removable
NCT ID NCT05099848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and results will show how many patients had successful surgery and how safe the treatment was.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 250117, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?